Actos Bladder Cancer Warning Added to Canadian Drug Label
Health Canada announced on April 19, 2012 that the country's warning labels would soon include Actos bladder cancer. The drug, which is prescribed to patients with type 2 diabetes, is allegedly linked to other serious risks, including Actos heart failure. The recent announcement, however, addresses only the risk of bladder cancer, which allegedly increases with higher dosages and/or long-term use of the medication. In the United States, Actos legislation has been consolidated into a federal MDL headquartered in Louisiana. In Canada, Actos lawsuits will be addressed by a country-wide class action suit.